Investing.com - Horizon Therapeutics (NASDAQ: HZNP) reported second quarter EPS of $1.20, $0.19 better than the analyst estimate of $1.01. Revenue for the quarter came in at $945M versus the consensus estimate of $897.62M.
Horizon Therapeutics's stock price closed at $101.14. It is down -8.08% in the last 3 months and up 50.69% in the last 12 months.
Horizon Therapeutics saw 1 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Horizon Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Horizon Therapeutics's Financial Health score is "great performance".
Check out Horizon Therapeutics's recent earnings performance, and Horizon Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar